Pre-Clinical in Vitro and in Vivo Evidence for Plausible Mechanisms Underlying the Risk of Cancer Associated with Insulin and Insulin Analogues.
Conclusion: In general many studies on pre-clinical in vitro and in vivo evidence for plausible mechanisms underlying the risk of cancer associated with insulin and insulin analogues exist. However, the level of evidence or a causal association between insulin and insulin analogues and cancer is low.
PMID: 24215309 [PubMed - as supplied by publisher] (Source: Current Drug Safety)
Source: Current Drug Safety - November 7, 2013 Category: Drugs & Pharmacology Authors: Vestergaard P, Starup-Linde J Tags: Curr Drug Saf Source Type: research
Safety of once‐daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice
ConclusionsOnce‐daily insulin detemir therapy was safe and effective, and rates of hypoglycemia were low. Concerns about hypoglycemia should not deter the initiation of basal insulin analogs. (Source: Journal of Diabetes)
Source: Journal of Diabetes - October 29, 2013 Category: Endocrinology Authors: Stuart Ross, Grzegorz Dzida, Qiuhe Ji, Marcel Kaiser, Robert Ligthelm, Luigi Meneghini, Avideh Nazeri, Domingo Orozco‐Beltran, Changyu Pan, Anne Louise Svendsen, Tags: Original Article Source Type: research
Basal insulin analogs: From pathophysiology to therapy. What we see, know, and try to comprehend?
Abstract
During the past 10years, several new basal insulin analogs have been developed. There has been for 3years controversy on the potential increased risk for cancer with insulin glargine, which ceased with the publication of the ORIGIN trial in 2012. In insulin-treated persons with type 2 diabetes, it is usual to recommend that plasma insulin concentrations remain within a 50-200pmol/L range in order to avoid overinsulinization, a potential causative factor for increased mitogenicity. Such concentrations are achieved when daily doses of insulin glargine or NPH insulin approximate 0.4 units/kg. However...
Source: Diabetes and Metabolism - October 17, 2013 Category: Endocrinology Authors: Monnier L, Colette C, Owens D Tags: Diabetes Metab Source Type: research
A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: A single dose clamp study in people with type 2 diabetes.
CONCLUSION: In persons with T2DM, no difference in duration of action following a single subcutaneous dose of insulin detemir and insulin glargine could be observed. Insulin detemir showed greater between subject variability and achieved a significantly higher maximum GIR than insulin glargine.
PMID: 24139704 [PubMed - as supplied by publisher] (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - October 16, 2013 Category: Endocrinology Authors: Luzio SD, Dunseath GJ, Atkinson MD, Owens DR Tags: Diabetes Metab Source Type: research
Determinants of Reversibility of Beta-cell Dysfunction in response to Short-term Intensive Insulin Therapy in Patients with early Type 2 Diabetes.
In conclusion, decline in HOMA-IR may be a key determinant of improvement of beta-cell function in response to short-term IIT, suggesting a fundamental contribution of insulin resistance to the reversible component of beta-cell dysfunction in early T2DM.
PMID: 24129396 [PubMed - as supplied by publisher] (Source: American Journal of Physiology. Endocrinology and Metabolism)
Source: American Journal of Physiology. Endocrinology and Metabolism - October 15, 2013 Category: Physiology Authors: Kramer CK, Choi H, Zinman B, Retnakaran R Tags: Am J Physiol Endocrinol Metab Source Type: research
Cerebral Blood Flow and Glucose Metabolism in Appetite-Related Brain Regions in Type 1 Diabetic Patients After Treatment With Insulin Detemir and NPH Insulin: A randomized-controlled crossover trial.
CONCLUSIONSTreatment with insulin detemir versus NPH insulin resulted in weight loss, paralleled by increased CBF in appetite-related brain regions in the resting state, in men with well-controlled type 1 diabetes. These findings lend support to the hypothesis that a differential effect on the brain may contribute to the consistently observed weight-sparing effect of insulin detemir.
PMID: 24130356 [PubMed - as supplied by publisher] (Source: Diabetes Care)
Source: Diabetes Care - October 15, 2013 Category: Endocrinology Authors: van Golen LW, Ijzerman RG, Huisman MC, Hensbergen JF, Hoogma RP, Drent ML, Lammertsma AA, Diamant M Tags: Diabetes Care Source Type: research
Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study
ConclusionsThere were considerable differences in risk of hospitalization or secondary healthcare visits due to hypoglycemic coma between basal insulin treatments in real‐life clinical practice. © 2013 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - October 1, 2013 Category: Drugs & Pharmacology Authors: Jari Haukka, Fabian Hoti, Panu Erästö, Tero Saukkonen, Sari Mäkimattila, Pasi Korhonen Tags: Original Report Source Type: research
Weight change upon once‐daily initiation of insulin detemir with or without dietary intervention in overweight or obese insulin‐naïve individuals with type 2 diabetes: results from the DIET trial
ConclusionThis study suggests that a modest dietary intervention plus basic lifestyle advice, compared with basic lifestyle advice alone, resulted in similar weight change, efficacy, safety and tolerability when initiating IDet once daily in overweight or obese insulin‐naïve individuals with type 2 diabetes. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - October 1, 2013 Category: Endocrinology Authors: K. Niswender, M. Piletic, H. Andersen, L. Conradsen Hiort, P. Hollander Tags: Original Paper Source Type: research
Safety of once‐daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents (OHAs) in routine clinical practice
ConclusionsOnce‐daily insulin detemir therapy was safe and effective, and rates of hypoglycemia were low. Concerns about hypoglycemia should not deter the initiation of basal insulin analogues. (Source: Journal of Diabetes)
Source: Journal of Diabetes - September 1, 2013 Category: Endocrinology Authors: Stuart Ross, Grzegorz Dzida, Qiuhe Ji, Marcel Kaiser, Robert Ligthelm, Luigi Meneghini, Avideh Nazeri, Domingo Orozco‐Beltran, Changyu Pan, Anne Louise Svendsen, Tags: Original Article Source Type: research
Insulin detemir in the management of type 2 diabetes in non-Western countries: Safety and effectiveness data from the A1chieve observational study
Abstract: Aims: This subgroup analysis of the A1chieve study examined data from 15,545 people who started treatment with insulin detemir±oral glucose-lowering drugs in routine clinical care.Methods: A1chieve was a 24-week, international, prospective, non-interventional study of people with type 2 diabetes from non-Western nations starting treatment with basal insulin detemir, bolus insulin aspart or biphasic insulin aspart 30, alone or in combination, to evaluate their safety and effectiveness in routine clinical practice.Results: HbA1c for the global cohort improved after 24 weeks from 9.5±1.6% by −2.0±1.6% [80±17 b...
Source: Diabetes Research and Clinical Practice - September 1, 2013 Category: Endocrinology Authors: Alexey Zilov, Nabil El Naggar, Siddharth Shah, Chunduo Shen, Jihad Haddad Tags: Clinical Care and Education Source Type: research
Pharmacodynamics of the long‐acting insulin analogues detemir and glargine following single‐doses and under steady‐state conditions in patients with type 1 diabetes
ConclusionsThe duration of action of IDet is 23 h (range: 4.0–30.0), while that of IGlar is 27 h (range: 10.5–29.0) (95% CI: −8.1, 0.6). This suggests both insulins can be used for once‐daily dosing, but individual needs must be considered. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - August 19, 2013 Category: Endocrinology Authors: G. Koehler, G. Treiber, A. Wutte, S. Korsatko, J. K. Mader, B. Semlitsch, T. R. Pieber Tags: ORIGINAL ARTICLE Source Type: research
Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study
Abstract: Aims: Biphasic insulin aspart 30 allows fewer daily injections versus basal-bolus insulin regimens, which may improve adherence and treatment outcome. This sub-analysis of the observational A1chieve study assessed clinical safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes previously receiving basal-bolus insulin regimens.Methods: A1chieve was an international, open-label, 24-week study in people with type 2 diabetes starting/switching to biphasic insulin aspart 30, insulin detemir or insulin aspart. This sub-analysis assessed patients switching from insulin glargine- or neutral...
Source: Primary Care Diabetes - August 16, 2013 Category: Primary Care Authors: Guillermo Dieuzeide, Lee-Ming Chuang, Abdulrahman Almaghamsi, Alexey Zilov, Jian-Wen Chen, Fernando J. Lavalle-González Tags: Original Research Source Type: research
Resource utilisation and quality of life following initiation of insulin detemir in patients with type 2 diabetes mellitus
ConclusionsInitiating basal insulin therapy resulted in a substantial decrease in HbA1c and improved patients’ perceptions of insulin treatment. (Source: International Journal of Clinical Practice)
Source: International Journal of Clinical Practice - July 22, 2013 Category: Internal Medicine Authors: A. Liebl, H. Andersen, A. L. Svendsen, J. Vora, J.‐F. Yale, Tags: Original Paper Source Type: research
Pharmacodynamics of the long‐acting insulin analogues detemir and glargine following single doses and under steady‐state conditions in patients with type 1 diabetes
ConclusionsThe duration of action of IDet is 23 h (range 4.0–30.0), while that of IGlar is 27 h (range 10.5–29.0) (95% CI: −8.1, 0.6). This suggests both insulins can be used for once‐daily dosing, but individual needs must be considered. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - July 12, 2013 Category: Endocrinology Authors: Gerd Koehler, Gerlies Treiber, Andrea Wutte, Stefan Korsatko, Julia K. Mader, Barbara Semlitsch, Thomas R. Pieber Tags: Original Article Source Type: research
One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target
Abstract: Aim: To investigate durability of efficacy and safety over 1year of the sequence of liraglutide added to metformin followed by add-on insulin detemir if glycated hemoglobin (HbA1c) remains ≥7.0%.Methods: Patients previously uncontrolled on metformin±sulfonylurea with HbA1c ≥7.0% after 12weeks of adding liraglutide 1.8mg to metformin (run-in; sulfonylurea discontinued) were randomized 1:1 to 52weeks’ open-label add-on detemir (randomized treatment [RT] group; n=162) or continuation without detemir (randomized control [RC] group; n=161). Patients with HbA1c (Source: Journal of Diabetes and Its Complications)
Source: Journal of Diabetes and Its Complications - June 10, 2013 Category: Endocrinology Authors: Julio Rosenstock, Helena W. Rodbard, Stephen C. Bain, David D’Alessio, Jochen Seufert, Anne B. Thomsen, Claus Bo Svendsen, J. Hans DeVries, on behalf of the Liraglutide-Detemir Study Group Tags: Clinical Trials Source Type: research
